title: Familial hypercholesterolaemia: new treatment options.
abstract: Familial hypercholesterolaemia is a relatively frequently occurring disease that is strongly associated with vascular disease. Current treatment with cholesterol-lowering agents is partly effective but shows variable responses between patients with familial hypercholesterolaemia. Recently, new cholesterol-lowering drugs have been developed. Here we describe the most promising of these new agents for which results from phase 2 or phase 3 trials are available. We will discuss the data regarding lipid-lowering potential and safety issues and speculate about the potential reductions of the residual risk of statin-treated FH patients.
authors.affiliation: Department of Vascular Medicine, Erasmus MC, Rotterdam, The Netherlands. m.ezzahti@erasmusmc.nl
authors.forename: M
authors.initials: M
authors.lastname: Ezzahti
authors.forename: E J G
authors.initials: EJ
authors.lastname: Sijbrands
authors.forename: M T
authors.initials: MT
authors.lastname: Mulder
authors.forename: J E
authors.initials: JE
authors.lastname: Roeters van Lennep
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000235:genetics; D009841:Oligonucleotides / Q000627:therapeutic use; D023303:Oxazolidinones / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; C473731:BMS201038; D001562:Benzimidazoles; D009841:Oligonucleotides; D023303:Oxazolidinones; C524142:mipomersen; C577155:evolocumab; C530884:anacetrapib; C571059:alirocumab